ADIAL PHARMACEUTICALS I-CW23 (ADILW)

0.0009  0 (-57.14%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ADIAL PHARMACEUTICALS I-CW23

NASDAQ:ADILW (7/27/2023, 7:00:00 PM)

0.0009

0 (-57.14%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap0
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

ADILW Daily chart

Company Profile

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

Company Info

ADIAL PHARMACEUTICALS I-CW23

ADILW News

News Image8 days ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial...

News Image16 days ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross...

News Image2 months ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...

News Image2 months ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

New patent strengthens Adial’s patent portfolio and covers AD04’s unique ability to target the serotonin transporter gene for the potential treatment of...

News Image2 months ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Expands patent estate covering Adial’s unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence...

News Image3 months ago - Adial Pharmaceuticals, IncAdial Announces Appointment of Tony Goodman as Chief Operating Officer

Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board...

ADILW Twits

Here you can normally see the latest stock twits on ADILW, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example